{"id":"W4402561806","doi":"10.1016/j.annonc.2024.08.064","title":"55P Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"FUJIFILM Toyama Chemical; Foundation Medicine; Genentech; Sirtex Medical; Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University; Astellas Pharma; Eisai; Seagen; MacroGenics; Revolution Medicines; Chugai Pharmaceutical; NGM Biopharmaceuticals; EMD Serono; XBiotech; BeiGene; Halozyme; Mirati Therapeutics; Agios Pharmaceuticals; Vertex Pharmaceuticals; Moderna; Pfizer; HCA Healthcare; NuCana; Incyte; Handok; Ipsen; Array BioPharma; Yuhan; Daiichi Sankyo Europe; Servier; Gilead Sciences; Mylan; LG Chem; Myriad Genetics; TG Therapeutics; Amgen; Jounce Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Gemcitabine; Durvalumab; Biliary tract cancer; Cisplatin; Topaz; Internal medicine; Oncology; Cancer; Chemotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003621274,0.0007113795,0.001285261,0.0008591204,0.0003974383,0.001169131,0.0008089445,0.0006591248,0.002971572],"category_scores_gemma":[0.003386428,0.0004914131,0.004018505,0.0009985289,0.0003067775,0.0008344451,0.000770328,0.001568152,0.0003388468],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007477365,"about_ca_system_score_gemma":0.0006397655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004010032,"about_ca_topic_score_gemma":0.006160675,"domain_scores_codex":[0.9983736,0.0006335753,0.0001330192,0.0003449993,0.0002778215,0.0002369009],"domain_scores_gemma":[0.9978012,0.0007756596,0.0006904852,0.0003281961,0.0001806753,0.0002236859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2951518,0.0006378784,0.5849058,0.0009364334,0.04039208,0.0004737666,0.0001933012,0.003882475,0.01172393,0.0006935069,0.00491918,0.05608986],"study_design_scores_gemma":[0.005914784,0.01158697,0.9587298,0.00003950598,0.01560129,0.0003288815,0.0000762265,0.001418425,0.001490831,0.0002890051,0.00449472,0.00002943579],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816934,0.004875639,0.0007780715,0.0001467976,0.00006848436,0.0001558238,0.009856555,0.00004857297,0.002376722],"genre_scores_gemma":[0.9877856,0.0005781516,0.0003616118,0.0001891309,0.00004186106,0.0001411915,0.009369015,0.00002922242,0.0015043],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004010032,"threshold_uncertainty_score":0.01915139,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09577148927491659,"score_gpt":0.4100607703411268,"score_spread":0.3142892810662102,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}